Table of Contents:
- Highlights in digestive oncology
- Encorafenib plus cetuximab significantly prolongs the survival of patients with BRAFV600E-mutant metastatic colorectal cancer
- Highlights in breast cancer
- Highlights in respiratory oncology
- Highlights in melanoma
- Long-term benefit with encorafenib/ binimetinib in patients with BRAFV600-mutated melanoma
- Highlights in geriatric oncology
- Highlights in head and neck cancer
- Highlights in gynaecological cancers
- Highlights in genito-urinary cancer
